Mesoblast Announce Heart Muscle Function Improved After Single, Lowest-Dose Injection Of "Off-The-Shelf" Stem Cells In Patients With Heart Failure
Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced positive three-month interim efficacy results from the first 20 patients enrolled in the Phase 2 heart failure trial of the proprietary allogeneic, or “off-the-shelf”, adult stem cell product Revascor(TM).
[Read the full article here]Related News:
First Group Of Heart Failure Patients Treated With "Off-The-Shelf" Adult Stem Cells Successfully Pass Key Safety Milestone
Mesoblast Ltd Receives Clearance To Begin First European Trial Of Allogeneic Or ‘Off-The-Shelf’ Stem Cell Treatment For Heart Attacks
Heart Failure May Be Cut by New Stem-Cell Treatment, Mesoblast Study Shows